Physician profile
Melissa Gregory
NPI 1073172490
$5,215.02
in general payments reported to CMS, 2019-2025
25 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $331 · 2023: $2,249 · 2024: $1,522 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,883.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,114.49 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $748.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $728.14 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $669.18 | 2022-2025 | |
| Lilly USA, LLC | $547.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $278.32 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.28 | 2022-2025 | Jardiance |
| Amgen INC. | $148.45 | 2022-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $135.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $119.39 | 2022-2023 | Xarelto |
| Dexcom, INC. | $99.17 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $49.85 | 2022-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.59 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $46.36 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $43.88 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $37.73 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.71 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $34.88 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $28.19 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $27.06 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $26.54 | 2022-2023 | |
| Inspire Medical Systems, INC. | $23.92 | 2025 | Inspire |
| Abbott Laboratories | $23.86 | 2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $16.43 | 2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.